ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
September 15 2021 - 6:30AM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC) issued the following
statement:
ChromaDex announced today plans to appeal a September 14
decision granting a Motion for Summary Judgment (MSJ) in its
lawsuit for patent infringement against Elysium Health, Inc.
(“Elysium”) in the United States District Court for the District of
Delaware. ChromaDex licenses U.S. Patent No. 8,383,086 (“the ’086
patent”) and U.S. Patent No. 8,197,807 (“the ’807 patent”) from the
Trustees of Dartmouth College, which give ChromaDex exclusive
rights to the leading NAD precursor nicotinamide riboside (NR).
ChromaDex retains a strong and growing intellectual property
portfolio for nicotinamide riboside, consisting of over 20
composition, process, and method of use patents for discoveries
relating to NR and other NAD+ (nicotinamide adenine dinucleotide)
precursors. ChromaDex’s Niagen® is backed by 13 published and
peer-reviewed clinical trials. Niagen® has achieved regulatory
acceptance by the world’s four leading regulatory bodies: the U.S.
FDA, Health Canada, the European Commission, and the Therapeutic
Goods Administration (TGA) of Australia.
A separate lawsuit filed by ChromaDex against Elysium in the
United States District Court for the Central District of
California, which is distinct from the Delaware case, is set to
begin trial on Tuesday, September 21.
For additional information about ChromaDex, please visit
www.chromadex.com.
About ChromaDex: ChromaDex Corp. is a global bioscience
company dedicated to healthy aging. The ChromaDex team, which
includes world-renowned scientists, is pioneering research on
nicotinamide adenine dinucleotide (NAD+), levels of which decline
with age. ChromaDex is the innovator behind NAD+ precursor
nicotinamide riboside (NR), commercialized as the flagship
ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors
are protected by ChromaDex’s patent portfolio. ChromaDex delivers
Niagen® as the sole active ingredient in its consumer product Tru
Niagen® available at www.truniagen.com and through partnerships
with global retailers and distributors. ChromaDex maintains a
website at www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the Company.
Forward-Looking Statements: This release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including statements
related to ChromaDex’s plans to file an appeal. Statements that are
not a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210915005420/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of Finance and Investor Relations
949-419-0288 ext. 127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024